Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
XL310
- Development stage
- Preclinical
- Lead developer
- XL-protein
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Peptides
- Administration
- Subcutaneous
01
Overview
XL310 is a preclinical-stage bispecific PASylated protein developed by XL-protein for the treatment of metabolic diseases, including obesity and type 2 diabetes. The therapeutic candidate is a fusion protein comprising exendin-4, a glucagon-like peptide-1 (GLP-1) receptor agonist, and Peptide YY (PYY), which targets the neuropeptide Y receptor Y2 (NPY2R). To enhance its pharmacokinetic profile, the bispecific construct is modified using XL-protein's proprietary PASylation technology, which involves the genetic fusion of a Pro-Ala-Ser (PAS) polypeptide sequence to increase the hydrodynamic volume and extend the plasma half-life. This dual-agonist approach is designed to leverage the complementary pathways of GLP-1 and PYY for improved appetite control and glycemic management.
02
Targets
GLP1R (GLP-1R)NPY2R (Neuropeptide Y receptor subtype 2)
Beyond the preview
Go deeper on XL310.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on XL310.